Ovarian Cancer Coverage from Every Angle

Yoland C. Antill, MD, on Using a PARP Inhibitor in Maintenance Therapy for Ovarian Cancer

Posted: Sunday, June 2, 2019

What is your perspective on using a PARP inhibitor for maintenance therapy in ovarian cancer in a patient who has had a less-than-robust response to a previous platinum-containing regimen?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.